Uniunea Europeană - română - EMA (European Medicines Agency)

regeneron uk limited - rilonacept - sindroamele periodice asociate criopirinei - imunosupresoare - rilonacept regeneron este indicat pentru tratamentul sindroamelor asociate cryopyrin periodice (capace) cu simptome severe, inclusiv sindrom auto-inflamatorii rece familiale (fcas) şi sindromul muckle-wells (dm), la adulţi şi copii cu vârsta de 12 ani şi mai vechi.

Uniunea Europeană - română - EMA (European Medicines Agency)

n.v. organon - desloratadina - rhinitis, allergic, perennial; urticaria; rhinitis, allergic, seasonal - antihistaminice pentru uz sistemic, - azomyr is indicated for the relief of symptoms associated with:allergic rhinitis (see section 5. 1)urticaria (see section 5.

Uniunea Europeană - română - EMA (European Medicines Agency)

sandoz gmbh - epoetină alfa - anemia; kidney failure, chronic - preparate antianemice - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients: , treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;, treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis;, treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e. statusul cardiovascular, anemie preexistentă la începerea chimioterapiei).

Uniunea Europeană - română - EMA (European Medicines Agency)

ratiopharm gmbh - desloratadina - rhinitis, allergic, perennial; urticaria; rhinitis, allergic, seasonal - antihistaminice pentru uz sistemic, - desloratadine ratiopharm is indicated in adults for the relief of symptoms associated with:allergic rhinitischronic idiopathic urticaria as initially diagnosed by a physician.

Uniunea Europeană - română - EMA (European Medicines Agency)

hexal ag - epoetină alfa - anemia; kidney failure, chronic; cancer - preparate antianemice - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients: , treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;, treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. tratamentul anemiei și reducerea necesarului de transfuzii la pacienții adulți tratați prin chimioterapie pentru tumori solide, maligne limfom sau mielom multiplu, și la riscul de transfuzie cum a fost evaluată de starea generală a pacientului (e. statusul cardiovascular, anemie preexistentă la începerea chimioterapiei).

Uniunea Europeană - română - EMA (European Medicines Agency)

substipharm - raloxifen clorhidrat - osteoporoza, postmenopauză - hormoni sexuali și modulatori ai sistemului genital, - evista este indicat pentru tratamentul și prevenirea osteoporozei la femeile aflate în post-menopauză. sa demonstrat o reducere semnificativă a incidenței fracturilor vertebrale, dar nu și a șoldului. when determining the choice of evista or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits.

Uniunea Europeană - română - EMA (European Medicines Agency)

novartis europharm limited - ruxolitinib (sub formă de fosfat) - myeloproliferative disorders; polycythemia vera; graft vs host disease - agenți antineoplazici - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. policitemie vera (pv)jakavi este indicat pentru tratamentul pacienților adulți cu policitemie vera, care sunt rezistente la sau intoleranță la hidroxiuree. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.

Uniunea Europeană - română - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - anakinra - arthritis, rheumatoid; covid-19 virus infection - imunosupresoare - rheumatoid arthritis (ra)kineret is indicated in adults for the treatment of the signs and symptoms of ra in combination with methotrexate, with an inadequate response to methotrexate alone. covid-19kineret is indicated for the treatment of coronavirus disease 2019 (covid-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (supar) ≥ 6 ng/ml. periodic fever syndromeskineret is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above:cryopyrin-associated periodic syndromes (caps)kineret is indicated for the treatment of caps, including:neonatal-onset multisystem inflammatory disease (nomid) / chronic infantile neurological, cutaneous, articular syndrome (cinca)muckle-wells syndrome (mws)familial cold autoinflammatory syndrome (fcas)familial mediterranean fever (fmf)kineret is indicated for the treatment of familial mediterranean fever (fmf). kineret ar trebui să fie administrat în asociere cu colchicina, dacă este cazul. Încă e diseasekineret este indicat la adulți, adolescenți, copii și sugari cu vârsta de 8 luni și mai mari, cu o greutate de 10 kg sau mai mult pentru tratamentul de boala lui still, inclusiv sistemic, artrită idiopatică juvenilă (ajis) și adult-debut boala lui still (ordonatorii de credite subdelegați), cu active sistemice caracteristici ale moderat spre ridicat de activitate a bolii, sau la pacienții cu continuarea activității bolii după tratamentul cu medicamente non-steroidiene medicamente anti-inflamatorii (ains) sau glucocorticoizi. kineret poate fi administrat ca monoterapie sau în combinație cu alte medicamente anti-inflamatorii și medicamente antireumatice modificatoare ale bolii (marmb).

Uniunea Europeană - română - EMA (European Medicines Agency)

janssen-cilag international n.v. - palmitat de paliperidonă - schizofrenie - psiholeptice - xeplion este indicat pentru tratamentul de întreținere a schizofreniei la pacienții adulți stabilizați cu paliperidonă sau risperidonă. in selected adult patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, xeplion may be used without prior stabilisation with oral treatment if psychotic symptoms are mild to moderate and a long-acting injectable treatment is needed.

Uniunea Europeană - română - EMA (European Medicines Agency)

actavis group ptc ehf - reteplază - infarct miocardic - agenți antitrombotici - rapilysin is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent st elevation or recent left bundle branch block within 12 hours after the onset of acute-myocardial-infarction (ami) symptoms.